<i>Cordyceps</i> as a Natural Anticancer Agent: Molecular Mechanisms and Translational Promise
Cordyceps is a medicinal genus of entomopathogenic fungi, renowned for its long-standing use in traditional Asian medicine and its growing prominence in modern pharmacological research. Among its bioactive constituents, cordycepin (3�-deoxyadenosine), polysaccharides, and sterols have demonstrated significant anticancer properties across a variety of malignancies, including lung, liver, breast, and leukaemia models. Mechanistically, cordycepin induces apoptosis through mitochondrial and caspase-dependent pathways, inhibits cell proliferation by modulating key signalling cascades such as PI3K/Akt and mTOR, and exerts anti-angiogenic effects by downregulating VEGF. Additionally, Cordyceps extracts show potent immunomodulatory activity, enhancing macrophage and natural killer cell functions, which contribute to tumour suppression. In vitro and in vivo studies consistently support its role in tumour inhibition, while some early-phase clinical trials suggest safety and tolerability in adjunct cancer therapy. However, challenges such as standardisation of extracts, variability in active compound concentrations, and limited clinical data remain. As interest in natural product-based oncology therapies grows, Cordyceps represents a promising candidate for integrative cancer treatment strategies. Further molecular and clinical investigations are warranted to validate its therapeutic efficacy and unlock its full potential as a complementary anticancer agent. Major Findings: Cordyceps and its bioactive constituents, particularly cordycepin, exhibit significant anticancer activity through induction of apoptosis, inhibition of proliferation via PI3K/Akt and mTOR pathways, and anti-angiogenic effects. Additionally, strong immunomodulatory properties and consistent preclinical evidence highlight its potential as a complementary cancer therapy, although further clinical validation is required.